Knowledge HQ

This paper describes a knock-in strategy (KI-Ep) inserting a constitutive expression cassette into the CX3CR1 locus of HSPCs to regulate transgene expression. G-Rex systems were used for the long-term culture of edited HSPCs. The method enables low expression in stem cells and activation upon myeloid differentiation.

This study optimizes non-viral Sleeping Beauty CAR-CIK cell production. Switching from T-flasks to G-Rex reduced handling time and produced less differentiated cells with enhanced metabolic fitness and in vivo efficacy. The method was validated in GMP conditions for clinical scalability.

This study evaluates a fully enclosed CAR-T manufacturing process eliminating biosafety cabinets. It uses CellSeal Connect vials for cryopreservation and G-Rex for cell activation and expansion. Results show comparable cell expansion, viability, and transduction to standard open processes.

This study presents the design of a phase I clinical trial for NEXTGEN-TIL, a product selected for neoantigen recognition in solid tumors. It details preclinical expansion from biopsies. G-Rex vessels were used for clinical-scale GMP validation of the rapid expansion protocol (REP) to obtain sufficient cell doses.

This study compares Solupore and electroporation for manufacturing multi-edited CAR-T cells. Solupore-transfected cells showed higher viability, TSCM retention, and in vivo efficacy. 24-well G-Rex were used to assess cell proliferation and cytokine production, supporting metabolic health analysis.

This poster evaluates cGMP T cell expansion protocols using ImmunoCult reagents across G-Rex (6M plate and 50M bottle), Xuri, and PBS-MINI bioreactors. G-Rex produced high cell densities and yields of functional T cells, including central memory subsets, suitable for clinical manufacturing.

This study describes the MC3 protocol for lung TIL manufacturing, which simplifies the process by using G-Rex for both preREP and REP phases and replacing feeder cells with CD3/CD28 nanobeads. The method reduced culture time and costs while producing TILs with superior cytotoxicity against tumor organoids.

The authors developed 'enGager', a Cas9 fusion system that tethers cssDNA donors to enhance non-viral targeted integration. Used to engineer CD19/CD22 dual CAR-T cells. Post-electroporation, T cells were transferred to G-Rex 24-well plates for expansion, achieving high knock-in efficiency and cell viability.

This abstract presents SENTI-202, a logic-gated CAR-NK therapy for AML. The EMCN inhibitory CAR protects healthy HSCs from off-tumor toxicity. R&D scale CAR-NK cell manufacturing utilized 1L G-Rex for expansion, achieving high cell numbers and viability while maintaining logic gate function.

This study demonstrates that tuning the affinity of the TAC receptor's TCR-binding domain improves in vivo anti-tumor potency. CLDN18.2-TAC T cells were engineered and expanded using the G-Rex system. Lower affinity UCHT1 variants led to superior functional outcomes in solid tumor models.

This review analyzes automated cell therapy manufacturing systems. It highlights the G-Rex as a key technology for simplified static expansion compared to flasks. It notes that the Multiply Labs robotic cluster integrates G-Rex 100M for automated, parallel T cell expansion.

This study establishes an optimized platform for expanding and genetically modifying NK cells. Using KBM581 medium with serum replacement in 24-well G-Rex plates, the authors achieved over 5000-fold expansion in 14 days. The protocol supports efficient viral transduction and gene editing of NK cells.